LianBio Past Earnings Performance

Past criteria checks 0/6

LianBio has been growing earnings at an average annual rate of 12.5%, while the Biotechs industry saw earnings growing at 12.7% annually.

Key information

12.5%

Earnings growth rate

75.8%

EPS growth rate

Biotechs Industry Growth	17.0%
Revenue growth rate	n/a
Return on equity	-37.3%
Net Margin	n/a
Last Earnings Update	30 Sep 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown
Beta

How LianBio makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:LIAN.Y Revenue, expenses and earnings (USD Millions)
Date	Earnings	G+A Expenses	R&D Expenses
30 Sep 23	-88	69	38
30 Jun 23	-86	68	37
31 Mar 23	-107	67	56
31 Dec 22	-110	68	58
30 Sep 22	-113	63	56
30 Jun 22	-104	55	52
31 Mar 22	-162	47	116
31 Dec 21	-196	38	157
30 Sep 21	-188	30	153
30 Jun 21	-295	23	265
31 Mar 21	-198	19	173
31 Dec 20	-140	15	120

Quality Earnings: LIAN.Y is currently unprofitable.

Growing Profit Margin: LIAN.Y is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: LIAN.Y is unprofitable, but has reduced losses over the past 5 years at a rate of 12.5% per year.

Accelerating Growth: Unable to compare LIAN.Y's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LIAN.Y is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).

Return on Equity

High ROE: LIAN.Y has a negative Return on Equity (-37.26%), as it is currently unprofitable.

LianBio Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Recent updates

LianBio(OTCPK:LIAN.Y) dropped from NASDAQ Composite Index

With No Cure In Sight, Drugs Firm LianBio Begins Exit Strategy

LianBio Intends to File Form 25 with SEC

LianBio Announces Chief Financial Officer Changes

LianBio Announces Chief Financial Officer Changes

Lianbio Announces Chief Executive Officer Changes

Concentra Biosciences, LLC cancelled the acquisition of LianBio (NasdaqGM:LIAN) from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others.

LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

New major risk - Revenue and earnings growth

LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023

Price target decreased by 19% to US$6.24

Forecast to breakeven in 2023

LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations

LianBio (NASDAQ:LIAN) Is In A Good Position To Deliver On Growth Plans

Lianbio Announces Marketing Approval of CAMZYOS®? (Mavacamten) in Singapore

LianBio Announces Marketing Approval of CAMZYOS(R) (mavacamten) in the Macau Special Administrative Region (SAR) of China

We're Hopeful That LianBio (NASDAQ:LIAN) Will Use Its Cash Wisely

Price target decreased to US$8.23

We Think LianBio (NASDAQ:LIAN) Can Afford To Drive Business Growth

LianBio Announces the Resignation of Debra Yu, M.D. as President and Chief Strategy Officer, Effective January 1, 2023

Less than half of directors are independent

Price target increased to US$12.00

LianBio Doses First Patient in Phase 1 Trial of BBP-398 in Chinese Patients with Advanced Solid Tumors

LianBio Doses First Patient in Registrational Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

Nanobiotix S.A. and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

Companies Like LianBio (NASDAQ:LIAN) Are In A Position To Invest In Growth

Lianbio Completes Enrollment in Pivotal Phase 3 EXPLORER-CNTrial of Mavacamten in Chinese Obstructive Hypertrophic Cardiomyopathy Patients

Will LianBio (NASDAQ:LIAN) Spend Its Cash Wisely?

LianBio Completes Phase 1 Pharmacokinetic Study of Mavacamten in Healthy Chinese Volunteers

U.S. Food and Drug Administration Approves Camzyos (Mavacamten) for the Treatment of Adults with Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Less than half of directors are independent

LianBio Announces Formation of Scientific Advisory Board

LianBio Appoints Wei Wei Chen to Board of Directors

LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market

Here's Why LianBio (NASDAQ:LIAN) Must Use Its Cash Wisely

Lianbio Announces First Patient Dosed in Registrational Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy

LianBio Announces Approval of Infigratinib Under Special Named Patient Program for the Treatment of Cholangiocarcinoma in the Pilot Zone of Hainan Province in China

No independent directors

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Revenue & Expenses Breakdown
Beta